The University of Connecticut’s athletic department will host four separate bone marrow registry drives throughout November. The drives were organized in honor of 8-year-old Ben Rabinowitz, who was ...
A donut-eating contest helped raise funds for 17-year-old Levi Atkins, who's battling Acute Myeloid Leukemia, while uniting ...
Brisa Aschebrook-Kilfoy, Associate Professor of Family Medicine at UChicago, is an expert in conducting environmental exposure assessments. She is actively leading efforts to build resources to study ...
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted ...
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...
Lea Ann Ragusin Photography At Texas Children's Hospital, Fivecoat's daughter Shelly McAfee and her husband Tyler McAfee were ...
Michael Andreeff, MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of ...
Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to Venetoclax. Recent preclinical studies and preliminary clinical ...
Moleculin Biotech (MBRX) announced new findings supporting the ability of Annamycin to overcome resistance to Venetoclax in acute myeloid leukemia. This includes data from preclinical in vitro studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback